[{"id":"bbdbf125-b47b-4c23-bbce-643e55074de0","acronym":"","url":"https://clinicaltrials.gov/study/NCT01222637","created_at":"2021-01-18T04:54:45.343Z","updated_at":"2024-07-02T16:36:29.826Z","phase":"Phase 1","brief_title":"CetuGEX™: Phase 1 Study in Cancer Patients","source_id_and_acronym":"NCT01222637","lead_sponsor":"Glycotope GmbH","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR positive","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CetuGEX (tomuzotuximab)"],"overall_status":"Completed","enrollment":" Enrollment 41","initiation":"Initiation: 08/01/2010","start_date":" 08/01/2010","primary_txt":" Primary completion: 08/01/2012","primary_completion_date":" 08/01/2012","study_txt":" Completion: 10/01/2013","study_completion_date":" 10/01/2013","last_update_posted":"2021-05-25"}]